E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Multiple sclerosis |
Multiple sclerose |
|
E.1.1.1 | Medical condition in easily understood language |
Multiple sclerosis |
Multiple sclerose |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of add-on high-dose simvastatin in MS patients treated with natalizumab or ocrelizumab for at least six months on whole brain atrophy rate. |
Onderzoeken van de effectiviteit van add-on hoge dosis simvastatine bij MS patiënten die ten minste 6 maanden met natalizumab of ocrelizumab behandeld worden op de hersenatrofie snelheid. |
|
E.2.2 | Secondary objectives of the trial |
1. To investigate the effect of add-on high-dose simvastatin in the above mentioned patient population on regional grey and white matter volumes.
2. To explore the potential of serum NfL as predictor of treatment response and disease progression.
3. To investigate the effect on clinical, other imaging and patient reported outcome measures of disability progression of add-on high-dose simvastatin treatment.
4. To assess safety and tolerability of simvastatin add-on to NTZ or OCR treatment.
5. To explore differences in efficacy on the described measures between subgroups based on demographics, MS subtype or disease modifying therapy.
|
1. Onderzoeken van de effectiviteit van add-on hoge dosis simvastatine in bovengenoemde populatie op regionale grijze en witte stof volumes.
2. De potentie van serum NfL als voorspeller van behandelrespons en ziekte progressie exploreren.
3. Het effect op klinische, andere beeldvormende en patiënt gerapporteerde uitkomstmaten van ziekte progressie van add-on hoge dosis simvastatine behandeling onderzoeken.
4. De veiligheid en verdraagbaarheid van add-on simvastatine bij natalizumab of ocrelizumab behandeling.
5. Bekijken van de verschillen in effectiviteit op de beschreven uitkomstmaten en veiligheid tussen subgroepen op basis van demografische gegevens, MS subtype en immunomodulerende behandeling. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Definite diagnosis of multiple sclerosis (MS) according to the revised McDonald 2017 criteria.
2. Treatment with ocrelizumab or natalizumab for at least 6 months prior to inclusion.
4. Age 18 to 65 years old.
5. EDSS score 3.0 – 7.0 (inclusive). |
1. Definitieve diagnose van MS volgens de gereviseerde McDonald 2017 criteria.
2. Behandeling met ocrelizumab of natalizumab voor ten minste 6 maanden voorafgaand aan inclusie.
3. Leeftijd 18 tot 65 jaar.
4. EDSS score 3.0 - 7.0 (inclusief). |
|
E.4 | Principal exclusion criteria |
1. MS relapse within 6 months of baseline visit, with or without treatment with steroids.
2. Use of immunomodulation or -suppression other than ocrelizumab or natalizumab within the previous 6 months.
3. Commencement of treatment with fampridine within 3 months of baseline visit.
4. Concomitant use of lipid lowering drugs or use within 6 months before baseline visit.
5. Concomitant use of potent CYP3A4 inhibitors.
6. (History of) hypersensitivity, muscular toxicity or other adverse reaction due to statin or fibrate use.
7. Any predisposing factor to rhabdomyolysis: renal impairment (creatinine clearance <70 mL/min), uncontrolled hypothyroidism, personal or familial history of hereditary muscular disorders, alcohol abuse (>14 standard drinks units per week).
8. Baseline serum creatine kinase (CK) levels of >5 x ULN (confirmed by second measurement within 5-7 days), or at least 3-fold increase from baseline with associated muscle symptoms.
9. Active liver disease or unexplained persistent elevations of serum transaminases 3 x ULN. |
1. MS exacerbatie doorgemaakt in 6 maanden voor baseline visit, met of zonder behandeling met steroïden.
2. Gebruik van andere immuunmodulerende of -suppressieve middelen dan ocrelizumab of natalizumab in de afgelopen 6 maanden.
3. Start van behandeling met fampridine in 3 maanden voor baseline visit.
4. Gelijktijdig gebruik van cholesterolverlagende middelen of gebruik in 6 maanden voor baseline visit.
5. Gelijktijdig gebruik van potente CYP3A4 remmers.
6. (Voorgeschiedenis van) overgevoeligheid, spier toxiciteit of andere ongewenste reactie door statine of fibraat gebruik.
7. Eén of meer factoren die risico op rhabdomyolyse verhogen: nierinsufficiëntie (creatinine klaring <70 mL/min), hypohtyreoïdie die niet onder controle is, erfelijke spieraandoening bij patiënt of in diens familie, alcohol misbruik (>14 eenheden per week).
8. Baseline serum creatine kinase (CK) levels >5 x ULN (bevestigd door tweede meting binnen 5-7 dagen), or ten minste 3 maal gestegen vanaf baseline met geassocieerde spiersymptomen.
9. Actieve leveraandoening of onverklaarde persistente verhoging van serum transaminases van > 3 x ULN. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The change in whole brain atrophy rate, comparing rates during 6-month run-in period to 18-month treatment period. |
De verandering in hersenatrofie snelheid, waarbij de snelheid tijdens een run-in periode van 6 maanden vergeleken wordt met een behandelperiode van 18 maanden. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Baseline (month 0)
- End of 6-month run-in period (month 6)
- After 6 month of simvastatin treatment (month 12)
- End of study (month 24) |
- Baseline (maand 0)
- Einde van run-in periode van 6 maanden (maand 6)
- Na 6 maanden simvastatine behandeling (maand 12)
- Einde van de studie (maand 24) |
|
E.5.2 | Secondary end point(s) |
Secondary outcome measures include clinical outcome measures (neurological exam, arm- and walking functions, cognitive functions), biochemical outcome measures (sNfL, multi-parameter analysis of peripheral blood mononuclear cells (PBMC) and serum cholesterol), other imaging outcome measures (regional white and gray matter atrophy rate, functional connectivity on brain MRI, OCT), patient-reported outcome measures (questionnaires on the impact of MS on arm function, walking function, neuropsychological status and quality of life) and safety and tolerability (incidence of (serious) adverse events, CK levels). |
De secundaire uitkomstmaten betreffen klinische uitkomstmaten (neurologisch onderzoek, arm- en loopfuncties, cognitieve functies), biochemische uitkomstmaten (sNfL, multi-parameter analyse van mononucleaire cellen in perifeer bloed (PBMC) en serum cholesterol), andere beeldvorming (regionale hersenatrofie snelheden, functionele connectiviteit op MRI, OCT), patiënt-gerapporteerde uitkomstmaten (vragenlijsten over impact van MS op armfunctie, loopfunctie, neuropsychologische status en kwaliteit van leven) en veiligheid en verdraagbaarheid (incidentie van (serious) adverse events, CK levels) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Clinical testing (EDSS, MSFC, BICAMS, 6MWTEC), OCT and questionnaires are performed at baseline, month 6, month 12 and month 24. Biochemical measures including serum NfL are measured at baseline, month 6, month 7 and every 3 months between month 9 and 24. Adverse events survey is collected at baseline, month 6, month 7, every 3 months between month 9 and 24. |
Klinische testen (EDSS, MSFC, BICAMS, 6MWTEC), OCT en vragenlijsten worden afgenomen op baseline, maand 6, maand 12 en maand 24. Biochemische eindpunten inclusief serum NfL worden gemeten op baseline, maand 6, maand 7 en elke 3 maanden tussen maand 9 en 24. Een adverse events vragenlijst wordt verzameld bij baseline, maand 6, maand 7 en elke 3 maanden tussen maand 9 en 24. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Run-in versus behandeling |
Run-in versus treatment |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |